IntelGenx settles its US patent litigation related to Forfivo XL(R) tablets
IntelGenx Corp, announced that it has settled its Paragraph IV litigation with Wockhardt Bio AG related to IntelGenx' Forfivo XL 450 mg tablets.
Under the terms of the settlement, Wockhardt has been granted the rights, with effect from January 15, 2018, to be the exclusive marketer and distributor of an authorised generic of Forfivo XL in the US.
The Company will hold a call to discuss the settlement on Wednesday, December 3, 2014.